Company profile
XBiotech Inc.
NASDAQ:XBITBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05098080 | phase1 | completed | 2023-04-10 | 2023-10-24 | XBiotech, Inc. | Hutrukin to Analyze Safety and PK in Healthy Volunteers |
| NCT05363917 | phase2 | unknown | 2022-06-15 | 2022-12-15 | XBiotech, Inc. | Natrunix Versus Methotrexate in Rheumatoid Arthritis |
| NCT06590090 | phase2 | not_yet_recruiting | 2026-07-15 | 2027-01-15 | XBiotech, Inc. | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment |
| NCT05363891 | phase2 | completed | 2023-08-08 | 2024-10-31 | XBiotech, Inc. | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis |
| NCT02357966 | phase1_2 | completed | 2015-05-01 | 2016-12-01 | XBiotech, Inc. | Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. |
FDA applications (0)
No records yet.